- Home
- PRTA
as 09-06-2024 4:00pm EST
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $58.83 | AVG Volume (30 days): | 290.0K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.69 - $56.04 | Next Earning Date: | 10-31-2024 |
| Revenue: | $217,246,000 | Revenue Growth: | 276.98% |
| Revenue Growth (this year): | 59.66% | Revenue Growth (next year): | -40.62% |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
Business Wire
9 days ago
Prothena to Participate in Upcoming Healthcare Conferences
Zacks
19 days ago
What Makes Prothena (PRTA) a New Buy Stock
Insider Monkey
21 days ago
Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks
MT Newswires
24 days ago
Oppenheimer Cuts Prothena Price Target to $62 From $66, Outperform Rating Maintained
Zacks
a month ago
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
Zacks
a month ago
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
Associated Press Finance
a month ago
Prothena: Q2 Earnings Snapshot
Business Wire
a month ago
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.